Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO, USA.
Eye (Lond). 2014 Jan;28(1):93-101. doi: 10.1038/eye.2013.240. Epub 2013 Nov 8.
Retinal hypoxia-mediated activation of the hypoxia-inducible factor (HIF pathway) leading to angiogenesis is a major signaling mechanism underlying a number of sight-threatening diseases. Inhibiting this signaling mechanism with an already approved therapeutic molecule may have promising anti-angiogenic role with fewer side effects. Hence, the primary objective of this study was to examine the expression of HIF-1α and VEGF in human retinal pigment epithelial cells treated with ritonavir under hypoxic and normoxic conditions.
ARPE-19 and D407 cells were cultured in normoxic or hypoxic conditions, alone or in the presence of ritonavir. Quantitative real-time polymerase chain reaction, immunoblot analysis, sandwich ELISA, endothelial cell proliferation, and cytotoxicity were performed.
A 12-h hypoxic exposure resulted in elevated mRNA expression levels of both HIF-1α and VEGF in ARPE-19 and D407 cells. Hence, this time point was selected for subsequent experiments. Presence of ritonavir in the culture medium strongly inhibited VEGF expression in a concentration-dependent manner under hypoxic conditions. Immunoblot analysis demonstrated a substantially reduced protein expression of HIF-1α in the presence of ritonavir. Further, hypoxic exposure-induced VEGF secretion was also inhibited by ritonavir, as demonstrated using ELISA. Finally, ritonavir significantly diminished the proliferation of choroid-retinal endothelial (RF/6A) cells demonstrating potential anti-angiogenic activity. Cytotoxicity studies showed that ritonavir is non-toxic to RPE cells.
This study demonstrates for the first time that ritonavir can inhibit HIF-1α and VEGF in ARPE-19 and D407 cells. Such inhibition may form a platform for application of ritonavir in the treatment of various ocular diseases.
视网膜缺氧介导的缺氧诱导因子(HIF)通路激活导致血管生成,这是许多威胁视力的疾病的主要信号机制。用已批准的治疗分子抑制这种信号机制可能具有有前途的抗血管生成作用,副作用较少。因此,本研究的主要目的是研究在缺氧和常氧条件下用利托那韦处理人视网膜色素上皮细胞(ARPE-19 和 D407 细胞)时 HIF-1α 和 VEGF 的表达。
在常氧或缺氧条件下,单独或存在利托那韦的情况下培养 ARPE-19 和 D407 细胞。进行实时定量聚合酶链反应、免疫印迹分析、夹心 ELISA、内皮细胞增殖和细胞毒性测定。
12 小时缺氧暴露导致 ARPE-19 和 D407 细胞中 HIF-1α 和 VEGF 的 mRNA 表达水平升高。因此,选择此时间点进行后续实验。在培养基中存在利托那韦强烈抑制缺氧条件下 VEGF 的表达,呈浓度依赖性。免疫印迹分析显示,利托那韦存在时 HIF-1α 的蛋白表达明显降低。此外,ELISA 显示缺氧暴露诱导的 VEGF 分泌也被利托那韦抑制。最后,利托那韦显著抑制脉络膜视网膜内皮(RF/6A)细胞的增殖,显示出潜在的抗血管生成活性。细胞毒性研究表明利托那韦对 RPE 细胞无毒性。
本研究首次证明利托那韦可抑制 ARPE-19 和 D407 细胞中的 HIF-1α 和 VEGF。这种抑制可能为利托那韦在治疗各种眼部疾病中的应用提供平台。